Clinical trials: Seasonal Allergic Rhinitis
Allergic Rhinitis
A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- NCT02557633
- Testing
- Grass MATA MPL 10200, Grass MATA MPL 18200
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Allergy Therapeutics
SAR
A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)
This study is an open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with SAR.
- Trial name
- NCT07459556
- Testing
- Stapokibart
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc.
Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis
This is a Prospective, Controlled, Double Blinded, Single Center, Randomized, 3 Arm, Parallel Assignment, Phase 1b/2a Study to assess the safety, tolerability, and preliminary efficacy of B244 delivered as an intranasal spray in…
- Conditions
- Allergic Rhinitis, Allergic Rhinitis Due to Grass Pollen, Healthy Volunteers
- Trial name
- NCT03290248
- Testing
- B244 suspension, Vehicle
- Where
- 2 sites in United States, Canada
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- AOBiome LLC
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients
The aim of the study is to establish the maximum tolerated dose of PURETHAL Mites that is achieved by 90% of the patients with less than 20% of the injections giving rise to a swelling of > 5 cm and the optimal regimen to reach…
- Trial name
- NCT00973453
- Testing
- PURETHAL Mites 20,000 AUeq/ml
- Where
- 6 sites in Germany
- Volunteers
- 48 people
- Sponsor
- HAL Allergy
Rhinitis, Allergic, Seasonal, Hay Fever
To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)
The primary objective of this study is to demonstrate the efficacy of ciclesonide applied as a nasal spray once daily in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.
- Trial name
- NCT00659841
- Testing
- Ciclesonide
- Where
- 6 sites in United States
- Volunteers
- 302 people
- Sponsor
- AstraZeneca
Birch Pollen Allergy, Grass Pollen Allergy
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, like allergic asthma, later in…
- Conditions
- Birch Pollen Allergy, Grass Pollen Allergy, House Dust Mite Allergy, Cat Allergy
- Trial name
- MADMAX (NCT04435678)
- Testing
- ALEX² test using the MAX 45k automated laboratory system
- Where
- 2 sites in Austria
- Volunteers
- 839 people
- Sponsor
- MacroArray Diagnostics GmbH
Perennial Allergic Rhinitis, Allergic Rhinitis
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.
- Conditions
- Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever
- Trial name
- NCT00163514
- Testing
- Ciclesonide
- Where
- 74 sites in United States, Canada
- Volunteers
- 636 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Seasonal
A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.
This is first-in-human phase 1/2 clinical trial to evaluate the safety, systemic and local reactogenicity of GNR-127 at the first stage in sequential cohorts of patients with allergic rhinitis with sensitization to the birch…
- Trial name
- NCT07155499
- Testing
- GNR-127, 20 mcg, GNR-127, 40 mcg, GNR-127, 80 mcg
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- AO GENERIUM
Allergic Rhinitis
Study of CM310 in Patients With Allergic Rhinitis
This study is a multicenter, single arm, open-label phase II clinical study mainly evaluating the safety of CM310 in patients with allergic rhinitis.
- Trial name
- NCT05908721
- Testing
- CM310
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Keymed Biosciences Co.Ltd
Seasonal Allergic Rhinitis
Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
To evaluate the therapeutic equivalence of the lest formulation of Mometasone Furoate Nasal Spray, 50 mcg to the marketed formulation NASONEX® (mometasone furoate monohydrate) Nasal Spray, 50 mcg/actuation in patients with…
- Trial name
- NCT02125253
- Testing
- Mometasone Furoate Nasal Spray, 50 mcg, Nasonex Nasal Spray, 50 mcg
- Where
- 10 sites in United States
- Volunteers
- 811 people
- Sponsor
- Amneal Pharmaceuticals, LLC
Hayfever, Rhinitis, Allergic, Seasonal
Study In Adults And Adolescents With Seasonal Allergic Rhinitis
The purpose of the study is to compare the efficacy and safety of an investigational nasal spray compared with placebo nasal spray in the treatment of seasonal allergic rhinitis.
- Conditions
- Hayfever, Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
- Trial name
- NCT00115622
- Testing
- fluticasone furoate
- Where
- 4 sites in United States
- Volunteers
- 304 people
- Sponsor
- GlaxoSmithKline
Allergen Immunotherapy
Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis
This is a Phase 1, first-in-human clinical trial to test a new treatment called ITI-9001 for people with allergies to Japanese Red Cedar (JRC) pollen-a common cause of seasonal allergies in Japan.
- Trial name
- NCT07726147
- Testing
- ITI-9001
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Immunomic Therapeutics, Inc.
Dermatitis, Atopic, Hay Fever
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in populations with atopic disorders.
- Trial name
- NCT00189917
- Testing
- IMVAMUNE (MVA-BN)
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Type I Hypersensitivity
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00118625
- Testing
- Tree MATA MPL
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Allergy Therapeutics
Allergic Rhinitis, Allergic Rhinoconjunctivitis
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
The objective of the present study is to characterize the dose-response relationship of PURETHAL® Mites with a nasal provocation test in order to support the optimal dose in terms of clinical efficacy and safety.
- Trial name
- NCT01438463
- Testing
- PURETHAL Mites 6,667 AU/ml, PURETHAL Mites 20,000 AU/ml, PURETHAL Mites 50,000 AU/ml
- Where
- 35 sites in Austria, Belgium and 3 more
- Volunteers
- 290 people
- Sponsor
- HAL Allergy
Seasonal Allergic Rhinitis
A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies
The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice daily in patients with seasonal allergic…
- Trial name
- NCT01368445
- Testing
- azelastine hydrochloride 0.15% Nasal Spray, Azelastine 0.1%, Nasal Spray
- Where
- 30 sites in United States
- Volunteers
- 617 people
- Sponsor
- Meda Pharmaceuticals
Seasonal Allergic Rhinitis (SAR), Allergic Rhinitis
Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis
This study is designed to evaluate the efficacy, safety, and tolerability of PL-14 Allergy Blocker compared to saline spray in adults with Seasonal Allergic Rhinitis (SAR).
- Trial name
- NCT07588672
- Testing
- PL-14 Allergy Blocker, Ayr® Saline Nasal Mist
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- Polyrizon Ltd.
Seasonal Allergic Rhinitis
A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
A study of the ability of montelukast to improve signs and symptoms of seasonal allergic rhinitis compared with placebo. Loratadine is included in the study as an active control.
- Trial name
- NCT00960141
- Testing
- montelukast sodium, Comparator: loratadine
- Volunteers
- 829 people
- Sponsor
- Organon and Co
Seasonal Allergic Rhinitis
Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)
A single-center, double-blind, placebo-controlled study of FDC olopatadine hydrochloride and mometasone furoate nasal spray (Molo; also referred as GSP 301) was conducted in subjects with seasonal allergic rhinitis.
- Trial name
- GSP 301- PoC (NCT03444506)
- Testing
- Molo 1 (also referred as GSP 301-2 NS), Molo 2 (also referred as GSP 301-1 NS), DYMISTA nasal spray
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Hypersensitivity
Skin Test Study of BM32
The aim of the present skin test study CS-BM32-001 is to evaluate whether the BM32 proteins exhibit low/no allergenic activity when applied by skin prick- and atopy patch testing to grass pollen allergic patients
- Trial name
- NCT01350635
- Testing
- BM32
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Biomay AG